Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for children and adults with asthma

Michaela Edwards; Andrew Gallagher; Parameswaran Nair; Stewart Drew; Aashish Vyas; Rashmi Sharma; Paul A Marsden; David JW Evans

doi:10.1002/14651858.CD012929

Alert

Some users are currently having issues accessing their saved searches, and not receiving their alerts. We are working on a fix and will update users as soon as possible.

If you are experiencing this issue, please contact [email protected]

The Cochrane Library

Trusted evidence. Informed decisions. Better health.

Browse Advanced search

Scolaris Language Selector Scolaris Language Selector

Scolaris Content Language Banner Portlet Scolaris Content Language Banner Portlet

Scolaris Content Display Scolaris Content Display

Unlock the full Protocol

Download PDF
- Full All content Full All content
Cite this Protocol

Print
0 Comment
Share
Follow

Contents

Supplementary materials

Search strategies

About this Review

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for children and adults with asthma

Authors' declarations of interest

Version published: 22 January 2018 Version history

https://doi.org/10.1002/14651858.CD012929

Collapse all Expand all

Abstract

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the efficacy and safety of anti‐interleukin‐13 or anti‐interleukin‐4 agents, compared with placebo, anti‐Immunoglobulin E agents, or anti‐interleukin‐5 agents, for the treatment of children, adolescents, or adults with asthma.

Unlock the full Protocol